GSK, Teva Face Antitrust Class Action Over Lamictal Deal

Law360, New York (February 23, 2012, 7:32 PM EST) -- A drug distributor lodged a putative antitrust class action against GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. in New Jersey federal court Wednesday, accusing the companies of conspiring to keep a generic epilepsy drug off the market in order to maximize profits.

Louisiana Wholesale Drug Co. Inc. filed the suit on behalf of all those who purchased Lamictal-brand lamotrigine tablets since February 2008, alleging that Teva put the brakes on a patent challenge to Lamictal in 2005 in order to strike a deal with GSK that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.